Compounded Semaglutide

GLP-1 Receptor Agonists Alternative Administration Methods

Innovative Approach to the Administration of GLP-1 Receptor Agonists 

The global use of GLP-1 receptor agonists has increased significantly as they are known for their effectiveness in improving blood sugar control, promoting weight loss, and having a lower risk of hypoglycemia than other alternatives. 

These medications, typically administered through injection, come in various forms, such as pens or pre-filled syringes. However, many patients and prescribers wish to avoid injections and the oral absorption of tablets is minimal (less than 1% according to RYBELSUS® labeling). For these reasons, a patent-pending compounded formulation of Semaglutide for sublingual administration may be preferable.

This unique formulation, prepared easily with just two ingredients – (1) RYBELSUS® tablets and (2) SubMagna™ HMW – is available with a prescription. It’s worth mentioning that this formulation avoids potential violations of molecular patents often associated with compounded injectable medications.

Work is underway on the links below, where extensive information about this patent-pending compounded formulation and white papers on Semaglutide and GLP-1 receptor agonist medications will be housed.

Use of GLP−1 Receptor Agonists for Weight Loss

The growing burden of obesity demands effective treatments. Among the available options, Glucagon-like peptide-1 receptor (GLP-1R) agonists emerge as promising players. These drugs mimic a gut hormone that regulates appetite and digestion, potentially offering a safe and effective approach to weight management.

Why GLP-1R agonists? They work by several mechanisms:

• Reducing appetite: They make you feel fuller for longer, leading to decreased calorie intake.

• Slowing digestion: They delay stomach emptying, promoting feelings of satiety.

• Boosting metabolism: They increase energy expenditure, helping you burn more calories.

Evidence speaks volumes: Studies show significant weight loss with GLP-1R agonists, exceeding what lifestyle changes alone can achieve. Additionally, they improve metabolic health, potentially reducing the risk of obesity-related diseases like diabetes and heart disease.

Research continues to explore their full potential, including combinations with other therapies and personalized treatment approaches.

While not a magic bullet, GLP-1R agonists offer a powerful weapon in the fight against obesity. Their effectiveness, safety, and long-term benefits make them a valuable tool for individuals struggling with weight management and its associated health risks.

Concerns About Semaglutide